{"id":90058,"date":"2026-06-22T21:46:27","date_gmt":"2026-06-22T21:46:27","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/90058\/"},"modified":"2026-06-22T21:46:27","modified_gmt":"2026-06-22T21:46:27","slug":"novartis-strikes-deal-with-uk-biotech-for-up-to-1-7-billion","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/90058\/","title":{"rendered":"Novartis Strikes Deal With UK Biotech for Up To $1.7 Billion"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/NOVN:SW\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Novartis AG<\/a> will pay UK biotech <a href=\"https:\/\/www.bloomberg.com\/quote\/2072274D:LN\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Relation Therapeutics Ltd.<\/a> as much as $1.7 billion to help find drug targets to treat allergic diseases.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">The Swiss drugmaker will pay $55 million upfront to combine its expertise in immuno-dermatology with the British firm\u2019s drug discovery AI platform, which uses patient data including from human tissue to unpack the genetic basis for how diseases present, Relation\u2019s Chief Executive Officer David Roblin said.<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis AG will pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug&hellip;\n","protected":false},"author":2,"featured_media":90059,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[225,114,7437,4397,45480,6107,4962,206,13223,11467,1106,23849],"class_list":["post-90058","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-artificial-intelligence","tag-business","tag-chief-executive-officer","tag-drugs","tag-fiona-h-marshall","tag-great-britain","tag-gsk-plc","tag-novartis","tag-novartis-ag-reg","tag-nvidia-corp","tag-united-kingdom","tag-venture-capital"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116795957854744054","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/90058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=90058"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/90058\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/90059"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=90058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=90058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=90058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}